Predictors of revision endoscopic sinus surgery in Finnish patients with chronic rhinosinusitis with nasal polyps

被引:0
作者
Toppila-Salmi, Sanna [1 ,2 ,3 ,4 ]
Lyly, Annina [5 ,6 ]
Simin, Johanna [7 ]
Aakko, Juhani [7 ]
Olsen, Helga Haugom [5 ]
Lehtimaki, Lauri [8 ,9 ]
机构
[1] Univ Eastern Finland, Dept Otorhinolaryngol, Kuopio, Finland
[2] Wellbeing Serv Cty Pohjois Savo, Dept Otorhinolaryngol, Kuopio, Finland
[3] Helsinki Univ Hosp, Inflammat Ctr, Dept Allergol, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
[5] AstraZeneca Nordics, Med Affairs, Espoo, Finland
[6] AstraZeneca Nordics, Med & Regulatory, Oslo, Norway
[7] Medaffcon Oy, Espoo, Finland
[8] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
[9] Tampere Univ Hosp, Allergy Ctr, Tampere, Finland
关键词
chronic rhinosinusitis; CRSwNP; endoscopic surgery; nasal polyps; revision surgery; PREVALENCE; GUIDELINES; OUTCOMES; ASTHMA;
D O I
10.1002/clt2.70032
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Although patients with chronic rhinosinusitis with nasal polyps (CRSwNP) may benefit from endoscopic sinus surgery (ESS), some patients will experience polyp recurrence, adding to the overall disease burden of CRSwNP. We aimed to investigate predictors of revision ESS in patients with CRSwNP. Methods A nationwide population-based study including all adults diagnosed with CRSwNP who had surgical procedure codes for ESS (N = 3506), followed up between January 2012 and December 2019. Logistic regression models provided adjusted odds ratios (OR) with 95% confidence intervals (CIs) for the odds of revision surgery within one and 3 years post-index surgery. Results 559 (15.9%) of the patients had at least one revision surgery during the follow-up. Median time to revision of ESS was 425 days (interquartile range: 213-898). Baseline asthma (OR = 1.58, 95% CI 1.17-2.12) and antibiotic use (OR = 1.61, 95% CI 1.27-2.04) were associated with higher odds of revision ESS, particularly within 3 years post-index surgery, whereas Increasing age was inversely associated with the odds of ESS revision (OR = 0.82, 95% CI 0.76-0.88). The highest odds of revision ESS were observed within 3 years post-index surgery in patients who had undergone extensive surgery at index (OR = 14.13, 95% CI 3.41-95.64) compared with those who had undergone limited surgery. OCS use was frequent among CRSwNP patients, with a higher cumulative dose in patients undergoing multiple ESS revisions (63%, n = 97, median daily dose 3.29 mg, IQR: 1.64-3.70) compared with patients without revisions (49%, n = 1361 and 1.64 mg, IQR: 1.64-3.29, respectively. p-value <0.001). Conclusions A small proportion of CRSwNP patients require revision ESS with associated high cumulative OCS doses, highlighting the need for additional therapies to achieve disease control and reduce the corticosteroid burden. A few simple baseline characteristics can predict the need for recurrent surgery among the patients with CRSwNP.
引用
收藏
页数:11
相关论文
共 41 条
[1]   Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials [J].
Bachert, Claus ;
Han, Joseph K. ;
Desrosiers, Martin ;
Hellings, Peter W. ;
Amin, Nikhil ;
Lee, Stella E. ;
Mullol, Joaquim ;
Greos, Leon S. ;
Bosso, John V. ;
Laidlaw, Tanya M. ;
Cervin, Anders U. ;
Maspero, Jorge F. ;
Hopkins, Claire ;
Olze, Heidi ;
Canonica, G. Walter ;
Paggiaro, Pierluigi ;
Cho, Seong H. ;
Fokkens, Wytske J. ;
Fujieda, Shigeharu ;
Zhang, Mei ;
Lu, Xin ;
Fan, Chunpeng ;
Draikiwicz, Steven ;
Kamat, Siddhesh A. ;
Khan, Asif ;
Pirozzi, Gianluca ;
Patel, Naimish ;
Graham, Neil M. H. ;
Ruddy, Marcella ;
Staudinger, Heribert ;
Weinreich, David ;
Stahl, Neil ;
Yancopoulos, George D. ;
Mannent, Leda P. .
LANCET, 2019, 394 (10209) :1638-1650
[2]   Factors Associated with Revision Sinus Surgery in Patients with Chronic Rhinosinusitis [J].
Bayer, Karina ;
Hamidovic, Selmir ;
Besser, Gerold ;
Mueller, Christian A. ;
Liu, David T. .
JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02)
[3]   Real-world characterisation of patients with chronic rhinosinusitis with nasal polyps with and without surgery in England [J].
Benson, Victoria S. ;
Fu, Qinggong ;
Yang, Shibing ;
Sousa, Ana R. ;
Chan, Robert H. ;
Howarth, Peter ;
Hopkins, Claire .
CLINICAL OTOLARYNGOLOGY, 2023, 48 (04) :680-688
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [J].
Chung, Kian Fan ;
Wenzel, Sally E. ;
Brozek, Jan L. ;
Bush, Andrew ;
Castro, Mario ;
Sterk, Peter J. ;
Adcock, Ian M. ;
Bateman, Eric D. ;
Bel, Elisabeth H. ;
Bleecker, Eugene R. ;
Boulet, Louis-Philippe ;
Brightling, Christopher ;
Chanez, Pascal ;
Dahlen, Sven-Erik ;
Djukanovic, Ratko ;
Frey, Urs ;
Gaga, Mina ;
Gibson, Peter ;
Hamid, Qutayba ;
Jajour, Nizar N. ;
Mauad, Thais ;
Sorkness, Ronald L. ;
Teague, W. Gerald .
EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) :343-373
[6]  
clinicaltrials, Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)
[7]  
clinicaltrials, Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
[8]   Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis [J].
Damask, Cecelia ;
Chen, Meng ;
Holweg, Cecile T. J. ;
Yoo, Bongin ;
Millette, Lauren A. ;
Franzese, Christine .
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2022, 36 (01) :135-141
[9]  
Dudecim Terveysportti, Pitkittynyt tai usein toistuva sivuontelotulehdus. Lkrin tietokannat
[10]  
Fokkens W, 2007, RHINOLOGY, P1